Quince Therapeutics Halts A-T Drug Development After Phase 3 Trial Miss
Quince Therapeutics ends eDSP development for ataxia-telangiectasia after Phase 3 NEAT trial fails primary endpoints. Stock plunges 91% as company explores strategic options.
/ 1 item
#QNCX↓